The bill amends K.S.A. 2024 Supp. 65-16,131 to expand the scope of practice for pharmacists in Kansas to include point-of-care testing for and treatment of COVID-19, alongside existing conditions such as influenza, streptococcal pharyngitis, and urinary tract infections. The collaborative drug therapy management advisory committee is tasked with establishing statewide protocols for these health conditions, which will outline the medications to be used, the qualifications required for pharmacists, documentation and record-keeping requirements, and communication protocols with patients' primary care providers.

Additionally, the bill includes provisions for the state board of pharmacy to deny applications or revoke licenses if pharmacists do not adhere to the established protocols. The existing section of K.S.A. 2024 Supp. 65-16,131 is repealed, and the new provisions will take effect upon publication in the statute book.

Statutes affected:
As introduced: 65-16